Future G protein-coupled receptor targets for treatment of heart failure

[1]  W. Koch,et al.  Myocardial Adeno-Associated Virus Serotype 6–&bgr;ARKct Gene Therapy Improves Cardiac Function and Normalizes the Neurohormonal Axis in Chronic Heart Failure , 2009, Circulation.

[2]  S. Houser,et al.  Cardiac‐Restricted Overexpression of the A2A‐Adenosine Receptor in FVB Mice Transiently Increases Contractile Performance and Rescues the Heart Failure Phenotype in Mice Overexpressing the A1‐Adenosine Receptor , 2008, Clinical and translational science.

[3]  David M. Harris,et al.  Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes , 2008, Proceedings of the National Academy of Sciences.

[4]  S. Houser,et al.  G Protein-Coupled Receptor Kinase 2 Ablation in Cardiac Myocytes Before or After Myocardial Infarction Prevents Heart Failure , 2008, Circulation research.

[5]  W. Koch,et al.  Gene therapy in heart failure. , 2008, Circulation research.

[6]  J. Spertus,et al.  A GRK5 polymorphism that inhibits β-adrenergic receptor signaling is protective in heart failure , 2008, Nature Medicine.

[7]  David M. Harris,et al.  Targeted Inhibition of Cardiomyocyte Gi Signaling Enhances Susceptibility to Apoptotic Cell Death in Response to Ischemic Stress , 2008, Circulation.

[8]  D. Webb,et al.  The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? , 2008, British journal of pharmacology.

[9]  W. Koch,et al.  Modulation of adrenal catecholamine secretion by in vivo gene transfer and manipulation of G protein-coupled receptor kinase-2 activity. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  S. Rasmussen,et al.  Signaling from β1- and β2-adrenergic receptors is defined by differential interactions with PDE4 , 2008, The EMBO journal.

[11]  J. Violin,et al.  β-Arrestin–mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection , 2007 .

[12]  S. Engelhardt.  Alternative signaling: cardiomyocyte beta1-adrenergic receptors signal through EGFRs. , 2007, The Journal of clinical investigation.

[13]  J. Violin,et al.  β-Arrestin-biased ligands at seven-transmembrane receptors , 2007 .

[14]  W. Koch,et al.  Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure , 2007, Nature Medicine.

[15]  S. Houser,et al.  Regulated Overexpression of the A1-Adenosine Receptor in Mice Results in Adverse but Reversible Changes in Cardiac Morphology and Function , 2006, Circulation.

[16]  J. Violin,et al.  β-Arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes , 2006, Proceedings of the National Academy of Sciences.

[17]  M. Gheorghiade,et al.  Pharmacological treatment of chronic heart failure , 2006, Heart Failure Reviews.

[18]  Robert J. Lefkowitz,et al.  Transduction of Receptor Signals by ß-Arrestins , 2005, Science.

[19]  E. Lakatta,et al.  Beneficial Effects of Chronic Pharmacological Manipulation of &bgr;-Adrenoreceptor Subtype Signaling in Rodent Dilated Ischemic Cardiomyopathy , 2004, Circulation.

[20]  D. Webb,et al.  Bradykinin Contributes to the Systemic Hemodynamic Effects of Chronic Angiotensin-Converting Enzyme Inhibition in Patients With Heart Failure , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[21]  N. Dzimiri,et al.  Differential functional expression of human myocardial G protein receptor kinases in left ventricular cardiac diseases. , 2004, European journal of pharmacology.

[22]  W. Koch,et al.  Targeted &bgr;-Adrenergic Receptor Kinase (&bgr;ARK1) Inhibition by Gene Transfer in Failing Human Hearts , 2004 .

[23]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[24]  M. Hori,et al.  Activation of Adenosine A1 Receptor Attenuates Cardiac Hypertrophy and Prevents Heart Failure in Murine Left Ventricular Pressure-Overload Model , 2003, Circulation research.

[25]  W. Koch,et al.  The β-adrenergic receptor kinase in heart failure , 2003 .

[26]  W. Welch,et al.  Adenosine A1 receptor antagonists and the kidney , 2003, Current opinion in nephrology and hypertension.

[27]  G. Nagy,et al.  Differential control of adrenal and sympathetic catecholamine release by alpha 2-adrenoceptor subtypes. , 2003, Molecular endocrinology.

[28]  J. Peart,et al.  Ischaemic Tolerance in Aged Mouse Myocardium: The Role of Adenosine and Effects of A1 Adenosine Receptor Overexpression , 2003, The Journal of physiology.

[29]  T. Isono,et al.  Chymase Inhibition Prevents Cardiac Fibrosis and Improves Diastolic Dysfunction in the Progression of Heart Failure , 2003, Circulation.

[30]  B. Berk.  Angiotensin Type 2 Receptor (AT2R): A Challenging Twin , 2003, Science's STKE.

[31]  S. Choufani,et al.  Function of the endothelinB receptor in cardiovascular physiology and pathophysiology , 2002 .

[32]  S. Gottlieb,et al.  BG9719 (CVT-124), an A1 Adenosine Receptor Antagonist, Protects Against the Decline in Renal Function Observed With Diuretic Therapy , 2002, Circulation.

[33]  Robert J. Lefkowitz,et al.  Seven-transmembrane-spanning receptors and heart function , 2002, Nature.

[34]  S. Kaul,et al.  High-Dose Recombinant Apolipoprotein A-IMilano Mobilizes Tissue Cholesterol and Rapidly Reduces Plaque Lipid and Macrophage Content in Apolipoprotein E-Deficient Mice: Potential Implications for Acute Plaque Stabilization , 2001, Circulation.

[35]  S. Emani,et al.  In Vivo Ventricular Gene Delivery of a &bgr;-Adrenergic Receptor Kinase Inhibitor to the Failing Heart Reverses Cardiac Dysfunction , 2001, Circulation.

[36]  B. Kobilka,et al.  Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[37]  B. Kobilka,et al.  Dual Modulation of Cell Survival and Cell Death by β2-Adrenergic Gi and Gs Signaling in Adult Mouse Cardiac Myocytes , 2000 .

[38]  R. Lefkowitz,et al.  Preservation of myocardial β-adrenergic receptor signaling delays the development of heart failure after myocardial infarction , 2000 .

[39]  G. Dorn,et al.  Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. , 2000, Circulation.

[40]  R. Dietz,et al.  Neurohumoral Blockade in CHF Management , 2000, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[41]  M. Bristow.  β-Adrenergic Receptor Blockade in Chronic Heart Failure , 2000 .

[42]  R. Lefkowitz,et al.  Hybrid transgenic mice reveal in vivo specificity of G protein-coupled receptor kinases in the heart. , 2000, Circulation research.

[43]  Catherine Communal,et al.  Opposing Effects of β1- and β2-Adrenergic Receptors on Cardiac Myocyte Apoptosis Role of a Pertussis Toxin–Sensitive G Protein , 1999 .

[44]  R. Lefkowitz,et al.  Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary beta2-adrenergic receptor gene delivery. , 1999, The Journal of clinical investigation.

[45]  M. Lohse,et al.  Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Marc G. Caron,et al.  Control of Myocardial Contractile Function by the Level of β-Adrenergic Receptor Kinase 1 in Gene-targeted Mice* , 1998, The Journal of Biological Chemistry.

[47]  R. Lefkowitz,et al.  Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. , 1995, Science.

[48]  P. Molinoff,et al.  International Union of Pharmacology nomenclature of adrenoceptors. , 1994, Pharmacological reviews.

[49]  R. Lefkowitz,et al.  The binding site for the beta gamma subunits of heterotrimeric G proteins on the beta-adrenergic receptor kinase. , 1993, The Journal of biological chemistry.

[50]  J. Thorner,et al.  Model systems for the study of seven-transmembrane-segment receptors. , 1991, Annual review of biochemistry.

[51]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.